Article Type
Original Research
Published
In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.
Category: Haematology and Oncology
Drugs in Context Haematology welcomes a broad range of article types including original research, study protocols and review articles.
In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.
Article Type
Original Research
Published
The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.
Article Type
Review
Published
Human plasma-derived factor VIII/von Willebrand factor complex concentrates are used to control bleeding in patients with von Willebrand disease (VWD) or haemophilia A (HA). This article provides an extensive overview of the molecular properties, in addition to pharmacokinetic, efficacy and safety data, and case studies of clinical experience of one such concentrate, Biostate.
Article Type
Review
Published
Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.
Article Type
Original Research
Published
Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.
